Business
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
RAHWAY, N.J., March 30, 2026--Enlicitide, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions Compared to Oral Non-Statin Therapies
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/665804608f51eda75eb4190435f3ecc4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YxA4EqmtM0JXry4zkpv6rQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNA--/https://media.zenfs.com/en/business-wire.com/665804608f51eda75eb4190435f3ecc4","width":480,"height":217}},"lazy":false},{"type":"text","content":"The Phase 3 CORALreef AddOn trial compared the efficacy and safety of enlicitide to bempedoic acid, ezetimibe or bempedoic acid with ezetimibe","length":142,"tagName":"p","attribs":{}},{"type":"text","content":"Enlicitide has the potential to be the first approved oral PCSK9 inhibitor designed to help address critical unmet needs for patients with hypercholesterolemia and help combat the ongoing cardiovascular (CV) epidemic","length":216,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J., March 30, 2026--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced detailed results from CORALreef AddOn, an active comparator study designed to evaluate the efficacy and safety of enlicitide decanoate compared to other oral non-statin therapies (bempedoic acid, ezetimibe or bempedoic acid with ezetimibe) when added to background statins in adults with hypercholesterolemia who have a history of or are at risk for atherosclerotic cardiovascular disease (ASCVD). This is the third positive Phase 3 study of enlicitide decanoate, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In the study, treatment with enlicitide resulted in statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) compared to bempedoic acid, ezetimibe or bempedoic acid with ezetimibe at eight weeks (day 56) of treatment. The observed LDL-C reduction resulted in greater LDL-C goal attainment with enlicitide than the comparators (secondary endpoint). These late-breaking data were presented today at the American College of Cardiology’s Annual Scientific Session and Expo (ACC.26) (Abstract #336-07) and published simultaneously in JACC.","length":1288,"tagName":"p"},{"type":"text","content":"Results from CORALreef AddOn sh...